Rapid Response: The promise and peril of engineering biology, w/Ginkgo Bioworks Reshma Shetty

Moderna's Covid-19 vaccine would not have scaled without Ginkgo Bioworks. Reshma Shetty, co-founder and COO of Ginkgo – slated to go public via SPAC acquisition at a reported $15 billion valuation – explains how biotech innovation can build a better future now. Ginkgo's platform already serves industries from food and agriculture, to materials, to healthcare. Shetty acknowledges that engineering genes is a high stakes pursuit, and says Ginkgo is trying to pair the ambition of Silicon Valley with a "higher level of care" than consumer tech companies like social media have demonstrated. The key, Shetty says, is creating an unstable equilibrium – propelling progress but not at the expense of principles. Read a transcript of this episode at: https://mastersofscale.com Subscribe to the Masters of Scale weekly newsletter at https://mastersofscale.com/subscribe See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Om Podcasten

Award-winning business advice from Silicon Valley and beyond. Iconic CEOs, from Nike to Netflix, Starbucks to Slack, share the strategies that helped them grow from startups into global brands — and to weather crisis when it strikes. On each episode of our classic format, founding host Reid Hoffman — LinkedIn cofounder, Greylock partner and legendary Silicon Valley investor — and a stellar lineup of guest hosts prove unconventional theories about how businesses scale. Guests share their stories of entrepreneurship, leadership, strategy, management, fundraising. You’ll hear the human journey, too — failures, setbacks, learnings. From our Rapid Response format, you can expect real-time wisdom from business leaders in fast-changing situations. Hosted by Bob Safian, past editor-in-chief of Fast Company, these episodes tackle crisis response, rebuilding, diversity & inclusion, leadership change and much more.